Hohl Benjamin 4
4 · Enliven Therapeutics, Inc. · Filed Aug 29, 2025
Insider Transaction Report
Form 4
Hohl Benjamin
CHIEF FINANCIAL OFFICER
Transactions
- Sale
Common Stock
2025-08-27$20.63/sh−3,250$67,039→ 23,000 total - Exercise/Conversion
Common Stock
2025-08-27$2.48/sh+3,250$8,060→ 26,250 total - Exercise/Conversion
Stock Option (right to buy)
2025-08-27−3,250→ 108,306 totalExercise: $2.48Exp: 2031-08-02→ Common Stock (3,250 underlying)
Footnotes (3)
- [F1]The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.
- [F2]This transaction was executed in multiple trades at prices ranging from $20.27 to $20.8689. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F3]All of the shares subject to this option are fully vested and exercisable as of the date hereof.